儿童期起病的埃文斯综合征:摆脱难治性免疫性血小板减少症
本文基于基因组学进展重新审视埃文斯综合征(ES),提出按既往已知原发免疫疾病中的分子变异对患者分类,为靶向治疗或骨髓移植开辟新途径,而非长期广泛免疫抑制或脾切除;近期全生命周期研究提示至少80%的儿科患者随年龄增长会出现各种临床或生物学免疫病理表现,需长期随访和专门过渡计划监测。
要点
- ES自1951年描述以来与慢性免疫性血小板减少症及并发或迟发的自身免疫性溶血性贫血或中性粒细胞减少相关。
- 基因组学进展开始按既往已知原发免疫疾病中的分子变异对ES患者分类,开辟靶向治疗或骨髓移植新途径。
- 近期全生命周期研究提示至少80%的儿科ES患者随年龄增长会出现各种临床或生物学免疫病理表现,需长期随访和专门过渡计划监测。
核心结论
- 基于基因组学进展,ES可按既往已知原发免疫疾病中的分子变异分类,为靶向治疗或骨髓移植开辟新途径,而非广泛长期免疫抑制或脾切除。
- 近期全生命周期研究提示至少80%的儿科ES患者随年龄增长会出现各种临床或生物学免疫病理表现,尽管血细胞减少已缓解,需长期随访和专门过渡计划监测以改善成年结局。
研究设计与样本
- 本文为基于近期基因组学进展的综述性文章,提出对ES的新观点。
主要发现
- ES自1951年Evans首次描述以来与慢性免疫性血小板减少症及并发或迟发的自身免疫性溶血性贫血或中性粒细胞减少相关。
- 数十年来ES病程预后差,常导致长期糖皮质激素暴露、多种针对T或B淋巴细胞的免疫抑制药物及脾切除。
- 基因组学进展开始按既往已知原发免疫疾病中的分子变异对患者分类。
- 近期全生命周期研究提示至少80%的儿科ES患者随年龄增长会出现各种临床或生物学免疫病理表现,尽管血细胞减少已缓解。
临床怎么用
- 作者提出基于基因组学分类的ES新观点,为靶向治疗或骨髓移植开辟新途径,而非广泛长期免疫抑制或脾切除。
- 作者认为儿科ES患者需长期随访和专门过渡计划监测以改善成年结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its first description by Evans in 1951, this syndrome has been linked to chronic immune thrombocytopenia with the concurrent or delayed onset of autoimmune haemolytic anaemia or neutropenia. For decades, the evolution of Evans syndrome (ES) has carried a poor prognosis and often resulted in chronic steroid exposure, multiple immune suppressing medications directed against T or B lymphocytes, and splenectomy. This paper presents a new view of ES based on recent advances in genomics which begin to classify patients based on their underlying molecular variants in previously described primary immune disorders. This has opened up new avenues of targeted therapy or bone marrow transplant at rather than broad long-term immune suppression or splenectomy. Importantly, recent studies of the full lifespan of ES suggest that at least 80% of those paediatric patients will progress to various clinical or biological immunopathological manifestations with age despite the resolution of their cytopenias. Those patients merit long-term follow-up and monitoring in dedicated transition programs to improve outcome at the adult age.
引用
- Aladjidi N, Pincez T, Rieux-Laucat F, et al. Paediatric-onset Evans syndrome: Breaking away from refractory immune thrombocytopenia. Br J Haematol. 2023. PMID: 37735545. doi:10.1111/bjh.19073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。